[go: up one dir, main page]

SG10201907677QA - Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. - Google Patents

Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.

Info

Publication number
SG10201907677QA
SG10201907677QA SG10201907677QA SG10201907677QA SG10201907677QA SG 10201907677Q A SG10201907677Q A SG 10201907677QA SG 10201907677Q A SG10201907677Q A SG 10201907677QA SG 10201907677Q A SG10201907677Q A SG 10201907677QA SG 10201907677Q A SG10201907677Q A SG 10201907677QA
Authority
SG
Singapore
Prior art keywords
formulations
prevention
treatment
peripheral neuropathy
associated diseases
Prior art date
Application number
SG10201907677QA
Inventor
Yin Sze Loh
Original Assignee
Yin Sze Loh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yin Sze Loh filed Critical Yin Sze Loh
Priority to SG10201907677QA priority Critical patent/SG10201907677QA/en
Priority to EP20854153.2A priority patent/EP4017496A4/en
Priority to KR1020227008958A priority patent/KR102852882B1/en
Priority to CA3151797A priority patent/CA3151797A1/en
Priority to CN202080071678.2A priority patent/CN114555091B/en
Priority to PCT/SG2020/050406 priority patent/WO2021034267A1/en
Priority to US17/636,917 priority patent/US20220387440A1/en
Priority to JP2022510956A priority patent/JP2022545223A/en
Priority to TW109124632A priority patent/TWI887256B/en
Publication of SG10201907677QA publication Critical patent/SG10201907677QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG10201907677QA 2019-08-20 2019-08-20 Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. SG10201907677QA (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SG10201907677QA SG10201907677QA (en) 2019-08-20 2019-08-20 Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.
EP20854153.2A EP4017496A4 (en) 2019-08-20 2020-07-14 Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases
KR1020227008958A KR102852882B1 (en) 2019-08-20 2020-07-14 Formulations for use in the prevention and/or treatment of peripheral neuropathy and related diseases
CA3151797A CA3151797A1 (en) 2019-08-20 2020-07-14 Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.
CN202080071678.2A CN114555091B (en) 2019-08-20 2020-07-14 Formulation for preventing and/or treating peripheral neuropathy and related diseases
PCT/SG2020/050406 WO2021034267A1 (en) 2019-08-20 2020-07-14 Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.
US17/636,917 US20220387440A1 (en) 2019-08-20 2020-07-14 Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases
JP2022510956A JP2022545223A (en) 2019-08-20 2020-07-14 Preparations for the prevention and/or treatment of peripheral neuropathy and related diseases
TW109124632A TWI887256B (en) 2019-08-20 2020-07-21 Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201907677QA SG10201907677QA (en) 2019-08-20 2019-08-20 Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.

Publications (1)

Publication Number Publication Date
SG10201907677QA true SG10201907677QA (en) 2021-03-30

Family

ID=74660762

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201907677QA SG10201907677QA (en) 2019-08-20 2019-08-20 Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.

Country Status (9)

Country Link
US (1) US20220387440A1 (en)
EP (1) EP4017496A4 (en)
JP (1) JP2022545223A (en)
KR (1) KR102852882B1 (en)
CN (1) CN114555091B (en)
CA (1) CA3151797A1 (en)
SG (1) SG10201907677QA (en)
TW (1) TWI887256B (en)
WO (1) WO2021034267A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024061971A1 (en) * 2022-09-21 2024-03-28 Wista Laboratories Ltd. Novel formulations and vehicles
WO2025091016A1 (en) * 2023-10-26 2025-05-01 Indiana University Research And Technology Corporation Compositions comprising p75ntr inhibitors and recombinant nerve growth factor and methods for the treatment of corneal diseases and disorders using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100816670B1 (en) * 2006-08-18 2008-03-27 국방과학연구소 Use of methylene blue to treat retinal damage and to protect the retina
CA2934578A1 (en) * 2013-12-20 2015-06-25 University Of Manitoba Compositions comprising muscarinic m1 receptor antagonists for treatment of non-diabetic peripheral neuropathies
US9867787B2 (en) * 2015-04-27 2018-01-16 The University Of Hong Kong Hypromellose-graft-chitosan and methods thereof for sustained drug delivery
WO2017132639A1 (en) * 2016-01-30 2017-08-03 The Board Of Trustees Of The Leland Stanford Junior University Light-activated anchoring of therapeutic factors to tissues
EP3654950A4 (en) * 2017-07-17 2021-04-21 Wolfcreek Biotech Pte Ltd Microparticle formulations for delivery of active agents

Also Published As

Publication number Publication date
CN114555091B (en) 2024-08-23
KR102852882B1 (en) 2025-09-02
US20220387440A1 (en) 2022-12-08
KR20220066060A (en) 2022-05-23
JP2022545223A (en) 2022-10-26
WO2021034267A1 (en) 2021-02-25
EP4017496A1 (en) 2022-06-29
TW202108144A (en) 2021-03-01
CA3151797A1 (en) 2021-02-25
EP4017496A4 (en) 2023-08-23
TWI887256B (en) 2025-06-21
CN114555091A (en) 2022-05-27

Similar Documents

Publication Publication Date Title
IL282629A (en) Formulation based on medicinal plant, part or extract of the it, use of the formulation and product comprising that formulation
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
PL3577135T3 (en) A pharmaceutical composition for use in the treatment or prevention of c5-related diseases
GB201915522D0 (en) Use of cannabidiol preparations in the treatment of absence epilepsy
IL289167A (en) 2h-indazole derivatives and their use in the treatment of disease
IL274578A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
PL3829628T3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease
PT3810128T (en) Compositions for treating and/or preventing protein-aggregation diseases
MX2020001632A (en) Compositions comprising bacterial strains.
IL289758B1 (en) Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries
WO2019175260A3 (en) Modified oligonucleotides for use in treatment of tauopathies
IL272495A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
SG10201907677QA (en) Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases.
PL3937948T3 (en) Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases
IL268131A (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease
PL3829553T3 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa
PL3713590T3 (en) Human beta 2 defensin for use in the prevention and treatment of graft-versus-host-disease
EP3646872A4 (en) Agent for preventing and/or treating alzheimer's disease
IL284298A (en) Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases
IL282718A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
PL3813843T3 (en) Composition for use in the prevention and/or treatment of osteoarticular diseases
IT201700109607A1 (en) Composition for use in the prevention and / or treatment of glaucoma.
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
HK40062286A (en) Barn dust extract for the prevention and treatment of diseases
PL4081507T3 (en) Chemical compounds targeting the eye and use thereof in the treatment of eye diseases